Development and Evaluation of a Quantitative Systems Pharmacology Model for Mechanism Interpretation and Efficacy Prediction of Atezolizumab in Combination with Carboplatin and Nab-Paclitaxel in Patients with Non-Small-Cell Lung Cancer

• Autori principali: Chen-Yu Wang (Autore), Hao-Ran Dai (Autore), Yu-Ping Tan (Autore), Di-Hong Yang (Autore), Xiao-Min Niu (Autore), Lu Han (Autore), Wen Wang (Autore), Ling-Ling Ma (Autore), Aleksi Julku (Autore), Zheng Jiao (Autore)
• Natura: Libro
• Pubblicazione: MDPI AG, 2024-02-01T00:00:00Z.
• Soggetti: article
• Accesso online: Connect to this object online.

Immunotherapy has shown clinical benefit in patients with non-small-cell lung cancer (NSCLC). Due to the limited response of monotherapy, combining immune checkpoint inhibitors (ICIs) and chemotherapy is considered a treatment option for advanced NSCLC. However, the mechanism of combined therapy and...